HEART FAILURE

Insuf Card 2016; 11 (3): 115-121

 

 

Pulmonary Arterial Hypertension in adults with congenital heart disease

Impact and result

Registry data GUTI-GUCH

 

 

Claudio Gabriel Moros, Marisa Pacheco Otero, Gianina Faliva, Maria del Carmen Rubio, Mariana Lopez Daneri, Isabel Torres, Ines Aballa, Alvaro Sosa Lipradi, Liliana Noemi Nicolosi, Maria Grippo

 

 

 

Introduction

 

Adult Congenital Heart Disease (ACHD) is one of the fastest growing cardiology subgroups in recent years, due to early diagnosis and advances in surgical and endovascular treatment. 85-90% of patients with congenital heart disease will get to the adulthood. The survival of these patients generates complications and sequela as result of hospitalizations rate and new surgeries, and others procedures.

From 5 to 10% estimated patients with ACHD develop Pulmonary Hypertension (PH) on its progression, being actually the most frequent cause of Pulmonary Arterial Hypertension (PAH) after the connective tissue disease. Its appearance relate to a worse prognostic of the patient.

The objective of the present study is to analyze the epidemiology characteristics, clinical and pharmacological treatment of patients with PAH and its survival impact.